Allergan (NYSE:AGN) said today that longtime CFO Jeff Edwards is stepping down to honor a commitment he made to his family earlier this year, replaced by treasurer Jim Hindman effective immediately.
Pershing Square Capital Management
Allergan-Valeant update: SEC launches Ackman probe, Allergan pays up to $588M for Liris bladder drug, Ackman dangles IPO
Abbott CEO chides critics of corporate inversions | Medtech Wall Street news for the week of July 21, 2014
Allergan cuts 1,500 jobs, faces SEC complaint
Updated July 21, 2014, at 12:40 p.m. EST with additional information on Allergan’s earnings.
A countdown to failure for Valeant’s hostile $53B Allergan takeover
Ocular Therapeutix looks to raise $80M in IPO | Medtech Wall Street news for the week of July 14, 2014
Covidien shareholder files class action lawsuit blocking company’s merger with Medtronic | The week in medtech M&A
Allergan renews fight against hostile Valeant takeover
Valeant, hedge fund look to oust Allergan board members | MassDevice.com On Call
MASSDEVICE ON CALL — Valeant Pharmaceuticals and its hedge fund partner, Pershing Square Capital Management, asked Allergan (NYSE:AGN) shareholders today to oust Allergan’s board and replace it with a slate of its own directors.
Allergan reveals FDA win, lobbies to keep Valeant out
Embattled device maker Allergan (NYSE:AGN) hopes it can keep unwelcome buyer Valeant Pharmaceuticals from getting its hands on the company’s advancing R&D pipeline.